User experienced hair thickening and slight regrowth using RU58841, Fin, DUT, and Minoxidil. They plan to get a hair transplant in Turkey for further improvement.
The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.
The conversation is about hair loss treatments, including dermarolling, Minoxidil, Finasteride, and RU58841. Users discuss their experiences, side effects, and application methods for these treatments.
The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.
Hair loss treatments Fin and Minoxidil failed for user. Suggested alternatives are 75mg oral spiro and RU58841, but concerns about low testosterone and self-esteem were raised.
The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.
People are discussing where to buy Alfatradiol in Canada, avoiding eBay due to past issues. They share experiences and links to potential sellers, with some users noting the lower potency of available Alfatradiol products.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
A user discusses affordable hair loss treatments in India, highlighting alcohol-free Minoxidil with Finasteride and Redensyl for $10. They also mention government-provided Minoxidil with alcohol and Finasteride pills at very low costs.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Using Dutasteride as a hair loss treatment and its potential benefits, including availability in certain countries without a prescription and lower side effects than Minoxidil or RU58841.
A user has been using minoxidil without noticing improvements and is considering adding tretinoin gel to their regimen before trying RU58841. They seek advice on how to mix and apply tretinoin with minoxidil, including concentration and application frequency.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.
The conversation humorously discusses starting treatments like finasteride, dutasteride, RU58841, and oral minoxidil for hair loss. It highlights the challenges and experiences associated with these treatments.
The conversation discusses a 5-month hair loss treatment regimen including finasteride, minoxidil, RU58841, dermapen (1.7mm), and ketoconazole shampoo, with noticeable hair regrowth. One user notes the hair appears thicker, while another mentions RU58841 is not doctor-recommended.
Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.
The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
41-year-old female experienced slow hair thinning, took finasteride for a year, then switched to spironolactone. Irregular periods occurred, seeking advice on long-term side effects and considering a third medication.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
The user is using spironolactone for AGA and is concerned about obtaining it in the U.S. without a prescription. They are seeking advice on how to get a prescription in the U.S. as an immigrant.
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
The user is concerned about hair loss and is using treatments like dutasteride, microneedling, and topical finasteride, while considering adding RU58841. They are also using Minoxidil on the temples and are worried about testosterone-related hair loss.
Users are concerned about inconsistencies in the packaging and form of a Minoxidil, finasteride, and Biotin blend from LockLab.co, with some receiving capsules and others tablets. Despite reassurances from customer service about changes due to maintenance, users remain skeptical about the product's authenticity and effectiveness.
Finding and comparing providers of hair loss treatments such as Finasteride, Minoxidil and potentially Dutasteride, RU58841 and other research chemicals; the user has created a website to track suppliers of these products around the world; and various online pharmacies are recommended, including those that ship to certain countries.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.